现在是:
 English |  加入收藏  | 设为首页 
 
 首页 | 研究院概况 | 科研中心设置 | 师资队伍 | 人才培养 | 交流合作 | 规章制度 | 人才招聘 | 技术平台 | 青大主页 
     师资队伍
 师资概况 
 教授 
 副教授 
 特聘教授 
 卓越人才 
 讲师 
 博士后 
 
当前位置: 首页>>师资队伍>>卓越人才>>正文
 

卓越人才:刘英

2022年07月14日 10:46  点击:[]

刘英,男,博士,讲师,硕士研究生导师。

个人简介

2015年毕业于大连理工大学生命科学与技术学院,获得工学博士学位,同年进入青岛大学转化医学研究院工作。2020年入选青岛大学青年卓越人才工程。从事专业为肿瘤分子生物学,基础医学。现为国际知名SCI期刊Oncology Letters客座编辑/编委会委员、山东省医学伦理学会理事、山东中西医结合学会细胞行为组学专业委员会委员、中国生物化学与分子生物学学会会员、中国细胞生物学学会会员。长期担任Trends in Genetics, EBioMedicine, Cancer Letters, Molecular Therapy Oncolytics以及中国细胞生物学学报等国际国内知名期刊特邀审稿人。课题组围绕核受体信号转导、蛋白质翻译后修饰、肿瘤生物学标志物鉴定、生物信息学等方向进行基础和应用研究。迄今为止,已在生物医学相关领域国际高水平期刊发表SCI论文40余篇,其中以第一作者或通讯作者发表SCI论文22篇,分别发表在Molecular Cancer, Molecular Therapy Nucleic Acid, EBioMedicine, Cancer Letters, Molecular Therapy Oncolytics, Frontiers in Oncology等国际著名杂志之上。研究成果获辽宁省自然科学学术成果奖一等奖1项、辽宁省自然科学学术成果奖三等奖1项、大连市科学技术奖励一等奖1项、大连市科学技术奖励二等奖1项、大连市自然科学优秀学术论文一等奖1项。目前,作为项目负责人主持国家自然科学基金、山东省自然科学基金、青岛市博士后应用研究等项目三项,参与国家自然科学基金等项目多项。

、主要研究方向

1核受体信号转导

2蛋白质翻译后修饰

3肿瘤生物标志物鉴定

4生物信息学分析

代表性科研成果#第一作者,*通讯作者)

1. Ying Liu#, Xiang Ao#, Wei Ding, Murugavel Ponnusamy, Wei Wu, Xiaodan Hao, Wanpeng Yu, Yifei Wang, Peifeng Li*, and Jianxun Wang* (2018). Critical role of FOXO3a in carcinogenesis. Molecular Cancer, 17(1):104. (IF: 41.444)

2. Ying Liu#,* (2019). Targeting the Non-Canonical AKT-FOXO3a Axis: A Potential Therapeutic Strategy for Oral Squamous Cell Carcinoma. EBioMedicine, 49:6-8. (IF: 11.205)

3. Ying Liu#,*, Xiang Ao, Wanpeng Yu, Yuan Zhang, and Jianxun Wang (2022). Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer. Molecular Therapy Nucleic Acid, 27:50-72. (IF: 10.183)

4. Ying Liu#,*, Yu Wang, Xiaoge Li, Yi Jia, Jianxun Wang, and Xiang Ao (2022). FOXO3a in cancer drug resistance. Cancer Letters, doi.org/10.1016/j.canlet.2022.215724. (IF: 9.756)

5. Ying Liu#, Wei Ding, Hu Ge, Murugavel Ponnusamy, Qiong Wang, Xiaodan Hao, Wei Wu, Yuan Zhang, Wanpeng Yu, Xiang Ao*, and Jianxun Wang* (2019). FOXK Transcription Factors: Regulation and Critical Role in Cancer. Cancer Letters, 458:1-12. (IF: 9.756)

6. Ying Liu#, Wei Ding, Wanpeng Yu, Yuan Zhang, Xiang Ao*, and Jianxun Wang* (2021). Long non-coding RNAsBiogenesis, functions, and clinical significance in gastric cancer. Molecular Therapy Oncolytics, 23:458-476. (IF: 6.311)

7. Ying Liu#,*, Xiang Ao, Yu Wang, Xiaoge Li, and Jianxun Wang (2022). Long non-coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance. Frontiers in Oncology, 12:841411. (IF: 5.738)

8. Ying Liu#,*, Xiang Ao, Guoqiang Ji, Yuan Zhang, Wanpeng Yu, and Jianxun Wang (2021). Mechanisms of action and clinical implications of microRNAs in the drug resistance of gastric cancer. Frontiers in Oncology, 11:768918. (IF: 5.738)

9. Ying Liu#,*, Xiang Ao, Yi Jia, Xiaoge Li, Yu Wang, and Jianxun Wang (2022). The FOXO family of transcription factors: key molecular playersin gastric cancer. Journal of Molecular Medicine, 100(7):997-1015. (Cover illustration) (IF: 5.606)

10. Xiang Ao#, Wei Ding, Yuan Zhang, Dan Ding, and Ying Liu* (2020).TCF21: a critical transcription factor in health and cancer. Journal of Molecular Medicine, 98(8):1055-1068. (IF: 5.606)

11. Wenwen Marin#,*, Dennis Marin, Xiang Ao, and Ying Liu* (2021). Mitochondria as a therapeutic target for cardiac ischemia reperfusion injury (Review). International Journal of Molecular Medicine. 47(2):485-499. (IF: 5.314)

12. Ying Liu#,*, Xiang Ao, Xuehao Zhou, Chengcheng Du, and Shouxiang Kuang (2022). The regulation of PBXs and their emerging role in cancer. Journal of Cellular and Molecular Medicine, 26(5):1363–1379. (IF: 5.295)

13. Ying Liu#, Xiang Ao#, Zhaojun Jia, Xiaoyan Bai, Zhaowei Xu, Gaolei Hu, Xiao Jiang, Min Chen, and Huijian Wu* (2015). FOXK2 Transcription Factor Suppresses ERα-positive Breast Cancer Cell Growth Through Down-Regulating the Stability of ERα via mechanism involving BRCA1/BARD1. Scientific Reports, 5:8796. (IF: 4.996)

14. Xinyu Liu#, Ying Liu#, Qianshan Wang, Siqi Song, Lingjun Feng*, and Chunying Shi* (2021). The alterations and potential roles of MCMs in breast cancer. Journal of Oncology, (IF: 4.501)

15. Xiang Ao#, Ying Liu#, Xiaoyan Bai, Xinjian Qu, Zhaowei Xu, Gaolei Hu, Min Chen, and Huijian Wu* (2015). Association betweenEHBP1rs721048(AG) polymorphism and Prostate Cancer Susceptibility: A Meta-Analysis of 17 Studies Involving 150,678 Subjects. OncoTargets and Therapy, 8:1671-80. (IF: 4.345)

16. Xinyu Liu#, Qianshan Wang, Siqi Song, Manman Feng, Xiaoya Wang, Ling Li, Ying Liu*, and Chunying Shi* (2021). Epithelial splicing regulatory protein 1 is overexpressed in breast cancer and predicts poor prognosis for breast cancer patients. Medical Science Monitor. 27:e931102. (IF: 3.386)

17. Ying Liu#, Dongdong Chen, Yongheng Xing, Nan Ge, Yuan Zhang, Jing Liu, Wei Zou* (2014). A new oxovanadium complex enhances renal function by improving insulin signaling pathway in diabetic mice. Journal of Diabetes and Its Complications, 28(3):265-72. (IF: 3.219)

18. Chao Qu#, Jia Sun#, Ying Liu#, Xiaobo Wang, Lifen Wang, Chao Han, Qian Chen, Tianhui Guan, Hongyan Li, Yejun Zhang, Yang Wang, Jia Liu, Wei Zou*, and Jing Liu* (2018). Caveolin-1 Facilitated KCNA5 Expression, Promoting Breast Cancer Viability. Oncology Letters, 16(4):4829-4838. (IF: 3.111)

19. Ying Liu#, Xiang Ao, Qiong Wang, Jianxun Wang, Hu Ge* (2018). PiViewer: An open‐source tool for automated detection and display of π–π interactions. Chemical Biology & Drug Design, 92(4), 1809-1814. (IF: 2.873)

20. Xiang Ao#, Wei Ding, Hu Ge, Yuan Zhang, Dan Ding, and Ying Liu* (2020). PBX1 is a valuable prognostic biomarker for patients with breast cancer. Experimental and Therapeutic Medicine, 20(1):385-394. (IF: 2.751)

21. Baowei Li#, Xiong Wang#, Xiaodan Hao, Yanran Liu, Yin Wang, Chan Shan, Xiang Ao, Ying Liu*, Hongchu Bao*, and Peifeng Li* (2020). A novel c.2179T>C mutation blocked the intracellular transport of PHEX protein and caused X-linked hypophosphatemic rickets in a Chinese family. Molecular Genetics & Genomic Medicine, 8(8):e1262. (IF: 2.473)

22. Haotian Lu#, Chunying Shi#, Xinyu Liu, Chen Liang, Chaochao Yang, Xueqi Wan, Ling Li*, and Ying Liu* (2020). Identification of ZG16B as a prognostic biomarker in breast cancer. Open Medicine, 16(1):1-13. (IF: 2.123)

主持的科研项目

1、国家自然科学基金青年基金项目、81702785SUMO化修饰对FOXK2的调控及其在乳腺癌发生发展中的分子机制研究、2017/1-2020/1220万元主持。

2、山东省自然科学基金培养基金项目、ZR2017PH013FOXK2蛋白的SUMO化修饰对ERα阳性乳腺癌细胞增殖的影响及机制研究、2017/07-2018/124万元主持。

3、青岛市博士后应用研究项目、2016067FOXK2 SUMO化修饰对乳腺癌细胞增殖的调控机理、2016/11-2018/065万元主持。

五、科研奖励

1辽宁省自然科学学术成果奖一等奖1项(第1证书编号161803701433921

2、辽宁省自然科学学术成果奖三等奖1项(第2证书编号161803701433911

3、大连市自然科学优秀学术论文一等奖1项(第1证书编号2015-023

4、大连市科学技术奖励一等奖1项(第7证书编号2012J-1-09-10

5、大连市科学技术奖励二等奖1项(第6证书编号2016J-2-24-R07

六、主要荣誉称号

12021年度青岛大学转化医学研究院党支部优秀党员

22020年度青岛大学转化医学研究院党支部优秀党员

32019年度青岛大学转化医学研究院党支部优秀党员

42018年度青岛大学转化医学研究院党支部优秀党员

七、学术任职情况

1SCI期刊《Oncology LettersGuest Editor/Editorial Board Member

2、山东省医学伦理学会理事

3山东中西医结合学会细胞行为组学专业委员会委员

4中国生物化学与分子生物学学会会员

5中国细胞生物学学会会员

下一条:卓越人才:张银凤

关闭

Copyright ? 2016    qtm.qdu.edu.cn All Rights Reserved. 青岛大学转化医学研究院 版权所有

 

地址:青岛市登州路38号 邮编:266021 电话:0532-82991791 传真:0532-82991791
电子信箱:qdzhuanhua@sina.com/wangzhedong2014@hotmail.com